Sio Gene Therapies Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
SIOX
- Share Price
-
$0.40
- (As of Tuesday Closing)
Sio Gene Therapies General Information
Description
Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.
Contact Information
Website
www.siogtx.com
Formerly Known As
Roivant Neurosciences, Axovant Gene Therapies
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
PINX
Primary Office
- 130 West 42nd Street
- 26th floor
- New York, NY 10036
- United States
Sio Gene Therapies Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.40 | $0.41 | $0.23 - $0.75 | $29.7M | 74M | 631K | -$0.39 |
Sio Gene Therapies Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | (17,682) | (29,859) | 65,491 | 85,109 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (27,930) | (70,935) | (29,372) | (64,719) |
| Net Income | (28,829) | (71,887) | (32,425) | (72,628) |
| Total Assets | 47,272 | 75,080 | 135,147 | 93,680 |
| Total Debt | 0 | 2,516 | 1,243 | 16,391 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Sio Gene Therapies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sio Gene Therapies Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The c
Other Pharmaceuticals and Biotechnology
New York, NY
12
As of 2022
00000
00000000
00000
000000
ercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
0000 000000000
Coral Gables, FL
00
As of 0000
000.00
00000000
000.00
0000 0
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000 000000000
Cambridge, MA
000
As of 0000
00.000
000000000
00.000
Add Comparison
Sio Gene Therapies Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals | Corporation | Coral Gables, FL | 00 | 000.00 | 00000000 | 000.00 |
| 0000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
| 00000000 | Formerly VC-backed | Jersey City, NJ | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.00 | 00000000000 | 00.00 |
Sio Gene Therapies Patents
Sio Gene Therapies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220175962-A1 | Gene therapy compositions and methods for treating parkinson's disease | Pending | 10-Mar-2019 | 000000000 | |
| AU-2020236735-A1 | Gene therapy compositions and methods for treating parkinson's disease | Pending | 10-Mar-2019 | 0000000000 | |
| CA-3133188-A1 | Gene therapy compositions and methods for treating parkinson's disease | Pending | 10-Mar-2019 | 0000000000 | |
| EP-3937985-A1 | Gene therapy compositions and methods for treating parkinson's disease | Pending | 10-Mar-2019 | 0000000000 | |
| US-20190046506-A1 | Use of 5ht2a inverse agonists for treating psychosis | Inactive | 10-Aug-2017 | A61K31/415 |
Sio Gene Therapies Executive Team (19)
Sio Gene Therapies Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| Atul Pande MD | Self | Board Member | 000 0000 |
| Berndt Modig | Self | Board Member | 000 0000 |
| Eric Venker MD | Self | Board Member | 000 0000 |
| Frank Torti MD | Self | Chairman & Board Member | 000 0000 |
| Kristiina Vuori Ph.D | Self | Board Member | 000 0000 |
Sio Gene Therapies Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Sio Gene Therapies ESG
Risk Overview
Risk Rating
Updated June, 07, 2020
34.72 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 12,221
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 709
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 343
Rank
00.00
Percentile
